Published in Br J Dermatol on October 20, 2014
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors. Biologics (2015) 0.85
Advanced basal cell carcinoma: how rare is the diagnosis? Br J Dermatol (2014) 0.75
Aggressive basal cell carcinoma of the head and neck: challenges in surgical management. Eur Arch Otorhinolaryngol (2016) 0.75
A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma. J Skin Cancer (2017) 0.75
The MyoD DNA binding domain contains a recognition code for muscle-specific gene activation. Cell (1990) 7.94
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
MyoD1: a nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. Science (1988) 6.78
Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med (1999) 6.04
Identification of a new family of tissue-specific basic helix-loop-helix proteins with a two-hybrid system. Mol Cell Biol (1995) 5.71
Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med (1999) 3.37
Expression of transfected DNA depends on DNA topology. Cell (1986) 2.47
Use of a conditional MyoD transcription factor in studies of MyoD trans-activation and muscle determination. Proc Natl Acad Sci U S A (1993) 2.15
Myc and Max homologs in Drosophila. Science (1996) 1.85
Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood (2001) 1.74
Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol (1991) 1.68
Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health (1996) 1.65
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med (1991) 1.59
Effect of time of day and duration into shift on hazardous exposures to biological fluids. Acad Emerg Med (1996) 1.55
Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer (1997) 1.50
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res (2001) 1.42
In melanoma, beta-catenin is a suppressor of invasion. Oncogene (2011) 1.40
Missed epidemics and missing links: international birth cohort trends in multiple sclerosis. Eur J Neurol (2012) 1.39
The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther (1998) 1.36
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol (2001) 1.35
Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. Aviat Space Environ Med (2001) 1.33
MalaQuick versus ParaSight F as a diagnostic aid in travellers' malaria. Trans R Soc Trop Med Hyg (1999) 1.30
Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
Biomarkers in melanoma. Ann Oncol (2009) 1.17
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol (2011) 1.16
Cell sensitivity to gravity. Science (1984) 1.14
Cutaneous lymphomas consist of a spectrum of nosologically different entities including mycosis fungoides and small plaque parapsoriasis. Arch Dermatol (1996) 1.09
Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br J Dermatol (2003) 1.09
MyoD-positive myoblasts are present in mature fetal organs lacking skeletal muscle. J Cell Biol (2001) 1.08
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood (1998) 1.07
A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol (2008) 1.06
The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol (2007) 1.06
Is excessive running predictive of degenerative hip disease? Controlled study of former elite athletes. BMJ (1989) 1.06
The Mad protein family links transcriptional repression to cell differentiation. Cold Spring Harb Symp Quant Biol (1998) 1.02
Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer (2001) 1.02
Incidence and clinical features of traveler's diarrhea in infants and children. Pediatr Infect Dis J (1991) 1.00
Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. J Invest Dermatol (2001) 1.00
Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol (2000) 0.99
MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol (1997) 0.98
Urticarial vasculitis following cocaine use. Br J Dermatol (1999) 0.96
Survival and prognostic factors in patients with brain metastases from malignant melanoma. Onkologie (2004) 0.96
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer (2010) 0.96
Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. Chronobiol Int (1998) 0.95
Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. J Mol Med (Berl) (2001) 0.95
Exposure in vivo of agoraphobics: contributions of diazepam, group exposure, and anxiety evocation. Psychol Med (1976) 0.95
Epidermal H(2)O(2) accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: identification of a general mechanism in regulation of all 6BH4-dependent processes? J Invest Dermatol (2001) 0.94
Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res (1998) 0.94
Retinoic acid perturbs the expression of Xhox.lab genes and alters mesodermal determination in Xenopus laevis. Genes Dev (1991) 0.94
Behavioural aspects of travellers in their use of malaria presumptive treatment. Bull World Health Organ (1995) 0.94
Primary cutaneous lymphoma: two-decade comparison in a population of 263 cases from a Swiss tertiary referral centre. Br J Dermatol (2011) 0.94
Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res (1996) 0.94
Method for simultaneous RNA and DNA isolation from biopsy material, culture cells, plants and bacteria. Biotechniques (1997) 0.94
Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol (2006) 0.93
Cutaneous peripheral T-cell lymphomas, unspecified/NOS and rare subtypes: a heterogeneous group of challenging cutaneous lymphomas. G Ital Dermatol Venereol (2012) 0.93
Lymphocyte reactivity during spaceflight. Immunol Today (1985) 0.93
Trichogerminoma: a rare cutaneous adnexal tumor with differentiation toward the hair germ epithelium. Dermatology (2002) 0.92
Tolerance of mefloquine by SwissAir trainee pilots. Am J Trop Med Hyg (1997) 0.92
Baseline staging in cutaneous malignant melanoma. Br J Dermatol (2004) 0.92
Nocturnal activity and enuresis. A study of a 35 year old male. J Neurol Neurosurg Psychiatry (1974) 0.92
Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging (2009) 0.91
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol (2008) 0.91
SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol (2004) 0.91
Treatment of verrucous carcinoma with imiquimod and CO2 laser ablation. Dermatology (2003) 0.91
A theoretical study of the alkylation reaction of toluene with methanol catalyzed by acidic mordenite. J Am Chem Soc (2001) 0.90
TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer (2001) 0.90
Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. Ann Oncol (2008) 0.89
Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia. Int Arch Allergy Immunol (2001) 0.89
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. Ann Oncol (2014) 0.88
Glucagonoma syndrome and bronchial carcinoma. Ann Intern Med (1988) 0.88
ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clin Exp Immunol (2010) 0.87
The interleukin-2 receptor in lesions and serum of bullous pemphigoid. Arch Dermatol Res (1992) 0.87
Circulating intercellular adhesion molecule-1 in melanoma patients: induction by interleukin-2 therapy. J Immunother (1991) (1992) 0.87
Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer (2000) 0.87
Classification of cutaneous lymphomas. Dermatol Clin (1994) 0.87
A periodic DFT study of intramolecular isomerization reactions of toluene and xylenes catalyzed by acidic mordenite. J Am Chem Soc (2001) 0.87
Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol (2003) 0.86
Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol (1995) 0.86
Histological, immunological and molecular features of a nasal mucosa primary melanoma associated with nasal melanosis. Melanoma Res (2002) 0.86
Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells. Blood (1999) 0.86
Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related? Dermatology (2000) 0.86
Serum S100--a marker for disease monitoring in metastatic melanoma. Dermatology (1997) 0.86
Successful therapy of metastatic eccrine poroma using perilesional interferon alfa and interleukin 2. Arch Dermatol (1992) 0.86
Influence of ethanol on in vitro growth of human mammary carcinoma cell line MCF-7. Arch Gynecol Obstet (1996) 0.85
From inflammation to neoplasia: mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors. Arch Dermatol (2001) 0.85
Surgical pearl: mini-incisions for the extraction of steatocystoma multiplex. J Am Acad Dermatol (2001) 0.85
Effects of self-monitored jogging on physical fitness, blood pressure and serum lipids: a controlled study in sedentary middle-aged men. Int J Sports Med (1990) 0.85
Immune escape mechanisms in malignant melanoma. Int J Mol Med (1999) 0.85
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol (2004) 0.85
A realistic approach to the sensitivity of PCR-DGGE and its application as a sensitive tool for the detection of clonality in cutaneous T-cell proliferations. Exp Dermatol (1997) 0.85
Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res (2001) 0.84